文献速递妇科肿瘤

奥拉帕利联合贝伐珠单抗一线维持治疗卵巢癌:PAOLA-1/ENGOT-ov25 试验最终总生存结果

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
PubMed 文献 · Ann Oncol · 2023-05-19

PAOLA-1/ENGOT-ov25 最终总生存分析显示,在新诊断晚期卵巢癌一线含铂化疗联合贝伐珠单抗后临床缓解的患者中,奥拉帕利联合贝伐珠单抗维持治疗在意向治疗人群未显著改善总生存(HR 0.92,95%CI 0.76-1.12;P=0.4118),但在同源重组缺陷阳性人群中总生存延长(HR 0.62,95%CI 0.45-0.85;5年总生存率 65.5% 对 48.4%)。

要点

  • 意向治疗人群总生存无显著差异:中位 56.5 个月对 51.6 个月(HR 0.92,95%CI 0.76-1.12;P=0.4118)。
  • 同源重组缺陷阳性人群总生存延长:HR 0.62(95%CI 0.45-0.85),5年总生存率 65.5% 对 48.4%。
  • 同源重组缺陷阳性人群5年无进展生存率 46.1% 对 19.2%(HR 0.41,95%CI 0.32-0.54)。

核心结论

  • 奥拉帕利联合贝伐珠单抗为同源重组缺陷阳性的新诊断晚期卵巢癌一线患者提供了有临床意义的总生存改善,尽管安慰剂组进展后接受聚腺苷二磷酸核糖聚合酶抑制剂的比例较高,该联合方案仍被确认为该情形下的标准治疗之一,并具有提高治愈率的潜力。

研究设计与样本

  • PAOLA-1/ENGOT-ov25 试验的预设最终总生存分析,患者按 2:1 随机分配至奥拉帕利(300 mg 每日两次;最长 24 个月)联合贝伐珠单抗(15 mg/kg 每3周;总共15个月)组或安慰剂联合贝伐珠单抗组。
  • 总生存为关键次要终点,采用层级检验,计划在约60%成熟度或主要分析后3年时进行分析。
  • 奥拉帕利组和安慰剂组的中位随访时间分别为 61.7 个月和 61.9 个月。

主要发现

  • 意向治疗人群中,奥拉帕利组中位总生存 56.5 个月 vs 安慰剂组 51.6 个月(HR 0.92,95%CI 0.76-1.12;P=0.4118)。
  • 奥拉帕利组 105 例(19.6%)vs 安慰剂组 123 例(45.7%)后续接受了聚腺苷二磷酸核糖聚合酶抑制剂治疗。
  • 同源重组缺陷阳性人群中,奥拉帕利联合贝伐珠单抗组总生存更长(HR 0.62,95%CI 0.45-0.85;5年总生存率 65.5% 对 48.4%)。
  • 同源重组缺陷阳性人群中,5年时奥拉帕利联合贝伐珠单抗组无复发比例更高(HR 0.41,95%CI 0.32-0.54;5年无进展生存率 46.1% 对 19.2%)。
  • 骨髓增生异常综合征、急性髓系白血病、再生障碍性贫血及新发原发性恶性肿瘤发生率仍较低,两组间平衡。

关键数值与推荐

  • 同源重组缺陷阳性人群总生存:HR 0.62(95%CI 0.45-0.85),5年总生存率奥拉帕利联合组 65.5% 对安慰剂联合组 48.4%。
  • 同源重组缺陷阳性人群5年无进展生存率:奥拉帕利联合组 46.1% 对安慰剂联合组 19.2%(HR 0.41,95%CI 0.32-0.54)。
  • 意向治疗人群总生存:HR 0.92(95%CI 0.76-1.12;P=0.4118),中位奥拉帕利组 56.5 个月对安慰剂组 51.6 个月。

临床怎么用

  • 作者结论认为,奥拉帕利联合贝伐珠单抗为同源重组缺陷阳性的新诊断晚期卵巢癌一线患者提供了有临床意义的总生存改善。
  • 作者结论认为,该联合方案被确认为该情形下的标准治疗之一,并具有提高治愈率的潜力。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. PATIENTS AND METHODS: Patients were randomized 2 : 1 to olaparib (300 mg twice daily; up to 24 months) plus bevacizumab (15 mg/kg every 3 weeks; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. RESULTS: After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the intention-to-treat population [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.76-1.12; P = 0.4118]. Subsequent poly(ADP-ribose) polymerase inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR 0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR 0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. CONCLUSIONS: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving poly(ADP-ribose) polymerase inhibitors after progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023. PMID: 37211045. doi:10.1016/j.annonc.2023.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。